Glucocorticoid receptor–Retinoid X receptor alpha complex (GR–RXRA) (GR–RXRA)

The Glucocorticoid receptor–Retinoid X receptor (GR–RXR) complex is a functional protein-protein interaction between the ligand-activated transcription factor GR (NR3C1) and the Retinoid X Receptor (primarily RXRA). This interaction is a pivotal regulator of gene expression, particularly in the epidermis, where it mediates potent anti-inflammatory and tumor-suppressive effects (Indra et al., 2011, EMBO J). The complex functions primarily through transrepression, a process where the GR–RXR heterodimer antagonizes the activity of pro-inflammatory transcription factors such as AP-1 and NF-kappaB (Perez et al., 2012, J Invest Dermatol). In clinical contexts, the loss of either receptor or the disruption of their physical interaction is linked to the development of inflammatory disorders like psoriasis and malignancies such as cutaneous squamous cell carcinoma (UniProt, 2024). Drugs like dexamethasone and bexarotene target the individual components of this complex to modulate its activity, though their systemic use is often limited by side effects like skin atrophy and metabolic disturbances (StatPearls, 2023). Understanding this specific protein-protein interaction is vital for developing selective modulators that can achieve therapeutic efficacy with reduced toxicity.

Other names

NR3C1–RXRA complexGR–RXR heterodimerGlucocorticoid receptor–Retinoid X receptor alpha interactionGR–RXR protein–protein interaction

Modulation of gene transcription through the formation of a GR–RXR heterodimer, which facilitates transrepression of pro-inflammatory genes (e.g., via AP-1 and NF-kappaB inhibition) and synergistic activation of homeostatic genes.